The mRNA-1273.214 bivalent booster - Moderna bets on updated Covid protection
Published on 07/11/2026 at 09:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
The mRNA-1273.214 bivalent booster sits in a steel vaccine tray, tiny frost crystals still clinging to the vial as a nurse in Berlin rubs the label with her thumb. A few minutes later, Moderna scientist Stéphane Bancel is on screen, explaining why this updated shot matters for the next Covid season.
What the mRNA-1273.214 booster actually is
The mRNA-1273.214 bivalent booster is an updated version of Moderna’s original Covid-19 vaccine Spikevax, designed as a booster dose rather than for primary immunization. It combines mRNA sequences encoding the spike protein of the ancestral SARS-CoV-2 strain and of Omicron subvariants BA.4/BA.5 in a single formulation.
Moderna specifies that the bivalent booster is supplied as a frozen dispersion for intramuscular injection, typically given as a 0.5 ml booster dose in adults. The product builds on the same lipid nanoparticle technology as the original Spikevax, but adjusts the antigen mix to broaden immune coverage against circulating variants.
Dosing, storage and target groups
According to Moderna’s product information for Spikevax bivalent Original/Omicron BA.4-5 (mRNA-1273.214), the recommended booster dose for adults is 50 µg of mRNA in a 0.5 ml injection. National health authorities such as the European Medicines Agency and the U.S. Food and Drug Administration have authorized its use primarily as a booster in individuals 12 years and older, with specific age and prior vaccination criteria depending on the jurisdiction.
The vaccine is stored at -50 °C to -15 °C for long-term stability, with limited shelf life at refrigerated temperatures between 2 °C and 8 °C once thawed. In practice, that means hospital pharmacists and vaccination centers have to plan defrost cycles tightly; nurses often describe the thawed liquid as slightly cloudy but easy to draw up through standard needles, with no unusual odor.
How the Spikevax line feeds Moderna’s pipeline
For investors and healthcare professionals, the mRNA-1273.214 bivalent booster is part of Moderna’s broader strategy to keep Covid-19 vaccines relevant while funding the next generation of mRNA products.
Clinical data and variant coverage
In a Phase 2/3 clinical study, Moderna reported that the mRNA-1273.214 bivalent booster generated higher neutralizing antibody titers against Omicron BA.4/BA.5 compared to a booster with the original mRNA-1273 formulation. The company highlighted this advantage in a mid-2022 data release that later formed part of regulatory submissions in multiple regions.
Regulators have noted that the immunogenicity of mRNA-1273.214 remains robust against the ancestral strain, while improving responses to Omicron-lineage variants compared with the original vaccine. However, public-health agencies also emphasize that real-world effectiveness depends on the evolving variant landscape, local infection dynamics and the timing of booster campaigns.
Safety profile and side effects
Moderna states that the safety profile of the mRNA-1273.214 bivalent booster is broadly consistent with that of the original Spikevax vaccine. Commonly reported reactions in clinical trials include injection-site pain, fatigue, headache, muscle aches and chills, typically resolving within a few days.
Rare events such as myocarditis and pericarditis have been observed following mRNA Covid-19 vaccination, particularly in younger males, and health authorities continue to monitor these risks through pharmacovigilance systems. In practice, vaccinators now routinely inform patients about these signals, while underlining that the benefits of booster vaccination outweigh the known risks in approved age groups.
Production, logistics and pricing
For hospital buyers and national procurement agencies, the mRNA-1273.214 booster is usually not a product that appears with a public retail price tag. Instead, Moderna negotiates supply contracts with governments and multilateral organizations, often bundling volumes across seasons and formulations. Available disclosures suggest that per-dose prices for updated boosters in high-income markets have tended to be higher than during the early-pandemic emergency phase, but exact figures vary by country and are frequently confidential.
On the production side, Moderna has leaned heavily on its manufacturing network in the United States and Europe to scale bivalent boosters for seasonal demand. The company has also announced plans to localize mRNA manufacturing in additional regions, including partnerships in Australia, Canada and the United Kingdom, to shorten supply chains and add capacity for pandemic preparedness.
How mRNA-1273.214 fits into Moderna’s vaccine portfolio
Inside Moderna’s pipeline, the mRNA-1273.214 bivalent booster is part of a broader Spikevax family that now spans several Omicron-focused formulations and next-generation candidates. CEO Stéphane Bancel repeatedly frames Covid-19 as a "durable franchise" in earnings calls, stressing that updated boosters like mRNA-1273.214 help fund R&D in respiratory syncytial virus (RSV), influenza and combination vaccines.
Moderna is working on multivalent shots that combine Covid-19 and influenza antigens, aiming to reduce the number of injections for seasonal campaigns. In that context, mRNA-1273.214 acts as a bridge product: it keeps the Covid-19 line clinically and commercially relevant while the company tests more complex formulas in parallel.
Regulatory status and availability
The mRNA-1273.214 bivalent booster, branded in many markets as Spikevax bivalent Original/Omicron BA.4-5, has received authorizations or approvals from regulators such as the EMA and health authorities in various countries as an adapted Covid-19 vaccine. However, the exact status can change from season to season as regulators update recommendations and newer variant-adapted vaccines arrive.
In Europe, the bivalent booster has been available through national vaccination programs rather than over-the-counter channels. In the United States, updated formulations for each respiratory season are selected based on the most relevant variants, so the prominence of mRNA-1273.214 compared with later bivalents can shift over time as the Centers for Disease Control and Prevention and FDA update guidelines.
Investment context and Moderna stock
For retail investors, the mRNA-1273.214 bivalent booster matters because it illustrates how Moderna tries to turn its Covid-19 success into a recurring, though more volatile, revenue stream. Covid-19 vaccine sales, including bivalent boosters, have still been the dominant contributor to Moderna’s top line, even as demand has moderated compared with the height of the pandemic.
On the Nasdaq, the Moderna Inc. share (ISIN US60770K1079) reflects this shift from emergency-driven sales to a more typical vaccine market, where products like the mRNA-1273.214 booster have to compete seasonally and support the valuation while the rest of the pipeline matures.
Key facts at a glance
- Product: mRNA-1273.214 bivalent Covid-19 booster (Spikevax bivalent Original/Omicron BA.4-5)
- Manufacturer: Moderna Inc.
- Category: B2B/Pro line (vaccine for healthcare systems)
- Market launch: First authorizations for the mRNA-1273.214 bivalent booster were granted in 2022 in markets such as the EU and other regions.
- MSRP / Price: Supplied primarily through government and institutional procurement; specific per-dose prices are typically confidential and vary by country.
- Availability: Distributed via national vaccination programs in markets where authorized, subject to seasonal and regulatory decisions.
- Target group: Primarily adults and adolescents eligible for Covid-19 booster vaccination under local health authority guidelines.
- Highlight / USP: Combines ancestral and Omicron BA.4/BA.5 spike protein mRNA in one booster dose to broaden immune response.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
